Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Phase II study of R-CHOP followed by Y-90-ibritumomab tiuxetan in untreated mantle cell lymphoma: Eastern cooperative oncology group study E1499 49th Annual Meeting of the American-Society-of-Hematology Smith, M. R., Zhang, L., Gordon, L. I., Foran, J., Kahl, B., Gascoyne, R. D., Advani, R., Paietta, E., Weller, E., Horning, S. J. AMER SOC HEMATOLOGY. 2007: 121A–121A
View details for Web of Science ID 000251100800390